Fragment-based drug discovery and biological evaluation of novel cannabinol-based inhibitors of oxytosis/ferroptosis for neurological disorders.

Liang Z, Candib A, Soriano-Castell D, Fischer W, Finley K, Maher P. Fragment-based drug discovery and biological evaluation of novel cannabinol-based inhibitors of oxytosis/ferroptosis for neurological disorders. Redox Biol. 2024 Jun; 72:103138.

View in: PubMed

subject areas

Animals
Cannabinol
Disease Models, Animal
Drosophila
Drug Discovery
Humans
Mitochondria
Nervous System Diseases
Neurons
Neuroprotective Agents
Structure-Activity Relationship

authors with profiles

Kim Finley

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support